News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,157 Results
Type
Article (40569)
Company Profile (250)
Press Release (663337)
Multimedia
Podcasts (71)
Webinars (13)
Section
Business (204569)
Career Advice (2032)
Deals (35531)
Drug Delivery (98)
Drug Development (81385)
Employer Resources (173)
FDA (16281)
Job Trends (14936)
News (346098)
Policy (32744)
Tag
Academia (2566)
Accelerated approval (6)
Adcomms (24)
Allergies (89)
Alliances (49609)
ALS (101)
Alzheimer's disease (1411)
Antibody-drug conjugate (ADC) (154)
Approvals (16267)
Artificial intelligence (285)
Autoimmune disease (26)
Automation (18)
Bankruptcy (361)
Best Places to Work (11659)
BIOSECURE Act (20)
Biosimilars (110)
Biotechnology (176)
Bladder cancer (90)
Brain cancer (31)
Breast cancer (351)
Cancer (2678)
Cardiovascular disease (204)
Career advice (1695)
Career pathing (30)
CAR-T (175)
CDC (28)
Cell therapy (473)
Cervical cancer (20)
Clinical research (66668)
Collaboration (940)
Company closure (3)
Compensation (620)
Complete response letters (19)
COVID-19 (2729)
CRISPR (54)
C-suite (289)
Cystic fibrosis (108)
Data (2753)
Decentralized trials (2)
Denatured (19)
Depression (51)
Diabetes (297)
Diagnostics (6408)
Digital health (21)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (129)
Drug pricing (118)
Drug shortages (27)
Duchenne muscular dystrophy (115)
Earnings (87387)
Editorial (41)
Employer branding (22)
Employer resources (148)
Events (113540)
Executive appointments (817)
FDA (17782)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (848)
Gene editing (124)
Generative AI (20)
Gene therapy (356)
GLP-1 (752)
Government (4530)
Grass and pollen (4)
Guidances (179)
Healthcare (18865)
Huntington's disease (27)
IgA nephropathy (34)
Immunology and inflammation (136)
Immuno-oncology (5)
Indications (35)
Infectious disease (2889)
Inflammatory bowel disease (149)
Inflation Reduction Act (9)
Influenza (58)
Intellectual property (109)
Interviews (315)
IPO (16576)
IRA (45)
Job creations (3673)
Job search strategy (1439)
Kidney cancer (13)
Labor market (49)
Layoffs (490)
Leadership (17)
Legal (7975)
Liver cancer (77)
Lung cancer (377)
Lymphoma (190)
Machine learning (9)
Management (58)
Manufacturing (355)
MASH (83)
Medical device (13422)
Medtech (13427)
Mergers & acquisitions (19612)
Metabolic disorders (773)
Multiple sclerosis (93)
NASH (16)
Neurodegenerative disease (107)
Neuropsychiatric disorders (29)
Neuroscience (2039)
NextGen: Class of 2025 (6531)
Non-profit (4490)
Now hiring (45)
Obesity (403)
Opinion (219)
Ovarian cancer (94)
Pain (99)
Pancreatic cancer (104)
Parkinson's disease (172)
Partnered (22)
Patents (280)
Patient recruitment (135)
Peanut (48)
People (57693)
Pharmaceutical (63)
Pharmacy benefit managers (22)
Phase I (20784)
Phase II (29361)
Phase III (21888)
Pipeline (1543)
Policy (182)
Postmarket research (2569)
Preclinical (8836)
Press Release (64)
Prostate cancer (132)
Psychedelics (34)
Radiopharmaceuticals (252)
Rare diseases (433)
Real estate (5927)
Recruiting (66)
Regulatory (22528)
Reports (50)
Research institute (2329)
Resumes & cover letters (354)
Rett syndrome (9)
RNA editing (8)
RSV (51)
Schizophrenia (80)
Series A (144)
Series B (97)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (147)
Sponsored (30)
Startups (3604)
State (2)
Stomach cancer (13)
Supply chain (73)
Tariffs (57)
The Weekly (50)
Vaccines (797)
Venture capitalists (47)
Weight loss (252)
Women's health (41)
Worklife (16)
Date
Last 7 days (480)
Last 30 days (2344)
Last 365 days (31674)
2025 (14880)
2024 (35297)
2023 (40146)
2022 (51239)
2021 (55816)
2020 (54167)
2019 (46585)
2018 (35076)
2017 (32217)
2016 (31595)
2015 (37612)
2014 (31378)
2013 (26373)
2012 (28610)
2011 (29299)
2010 (27357)
Location
Africa (727)
Alabama (58)
Alaska (7)
Arizona (241)
Arkansas (13)
Asia (38195)
Australia (6225)
California (7078)
Canada (2238)
China (623)
Colorado (301)
Connecticut (304)
Delaware (178)
Europe (82105)
Florida (1061)
Georgia (235)
Idaho (58)
Illinois (606)
India (26)
Indiana (344)
Iowa (14)
Japan (208)
Kansas (108)
Kentucky (26)
Louisiana (13)
Maine (64)
Maryland (980)
Massachusetts (5245)
Michigan (238)
Minnesota (431)
Mississippi (3)
Missouri (85)
Montana (28)
Nebraska (25)
Nevada (77)
New Hampshire (65)
New Jersey (1962)
New Mexico (28)
New York (1987)
North Carolina (1041)
North Dakota (8)
Northern California (3122)
Ohio (226)
Oklahoma (15)
Oregon (34)
Pennsylvania (1538)
Puerto Rico (16)
Rhode Island (36)
South America (1103)
South Carolina (32)
South Dakota (1)
Southern California (2640)
Tennessee (118)
Texas (1049)
United States (26227)
Utah (209)
Virginia (171)
Washington D.C. (71)
Washington State (601)
West Virginia (4)
Wisconsin (62)
704,157 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially more than $4 billion.
May 20, 2025
·
1 min read
·
Annalee Armstrong
Earnings
Pfizer Announces Another $1.7B in Cost Savings, Including R&D Revamp
Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist Seagen. The new cuts were revealed in the company’s Q1 earnings report.
April 29, 2025
·
2 min read
·
Annalee Armstrong
Bladder cancer
Pfizer’s Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses Survival Endpoint
Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistence of cancer cells by 32% in patients with high-risk non-muscle invasive bladder cancer.
April 28, 2025
·
1 min read
·
Tristan Manalac
Adcomms
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support
The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in patients with prostate cancer who do not carry HRR mutations.
May 22, 2025
·
2 min read
·
Tristan Manalac
Vaccines
FDA Asks Pfizer/BioNTech, Moderna To Add Myocarditis Risk to COVID-19 Vaccines
The FDA had given Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge the agency’s directive. The products’ labels already include myocarditis warnings, albeit for different age groups.
May 22, 2025
·
2 min read
·
Tristan Manalac
Podcast
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.
April 16, 2025
·
1 min read
·
Heather McKenzie
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval; ODAC underway after chaotic planning; more.
May 21, 2025
·
2 min read
·
Heather McKenzie
Cardiovascular disease
Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market
Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
April 22, 2025
·
5 min read
·
Nick Paul Taylor
Weight Loss
Viking Rises as Pfizer’s Oral Obesity Med Falters
Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron. But the biotech has a long way to go to recover after six straight months of decline.
April 14, 2025
·
3 min read
·
Annalee Armstrong
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
·
2 min read
·
Tristan Manalac
1 of 70,416
Next
